Related Experiment Video
Updated: May 25, 2026
09:01
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157
P Sikiric1, S Seiwerth, R Rucman
1Department of Pharmacology, Medical Faculty University of Zagreb, Salata 11, POB 916, 10000 Zagreb, Croatia. sikiric@mef.hr
Current Medicinal Chemistry
|February 4, 2012
Summary
Stable gastric pentadecapeptide BPC 157 demonstrates significant potential for treating inflammatory bowel disease (IBD) and promoting wound healing. Its safety profile and efficacy in gastrointestinal tract conditions suggest a promising therapeutic agent.
Area of Science:
- Gastroenterology and Pharmacology
- Peptide Therapeutics
- Inflammatory Bowel Disease Research
Background:
- Stable gastric pentadecapeptide BPC 157 is a novel therapeutic agent with demonstrated efficacy in the gastrointestinal tract.
- BPC 157 exhibits an antiulcer effect and is effective in inflammatory bowel disease (IBD) therapy.
- The peptide has a favorable safety profile, with no observed toxic effects in trials.
Purpose of the Study:
- To evaluate the therapeutic potential of BPC 157 in inflammatory bowel disease (IBD) and gastrointestinal wound healing.
- To investigate the mechanism of action of BPC 157, including its interaction with the NO-system and its angiogenic effects.
- To assess the safety and tolerability of BPC 157 for long-term use in IBD therapy.
Main Methods:
- Review of preclinical animal studies and clinical phase II trials of BPC 157 (PL 14736).
- Analysis of BPC 157's effects on gastrointestinal healing, including intestinal anastomosis, short bowel syndrome, and fistula healing.
- Examination of BPC 157's interaction with the NO-system and its impact on gene expression related to inflammation and healing.
Main Results:
- BPC 157 demonstrated significant wound healing effects and potential in treating IBD.
- The peptide stimulates the expression of genes involved in cytokine and growth factor generation, promoting extracellular matrix formation.
- Studies indicated endothelium protection and angiogenic effects, even in compromised conditions.
Conclusions:
- BPC 157 shows high significance for future IBD therapy, supported by animal studies on advanced intestinal healing.
- Its safety profile and lack of toxicity make it a viable alternative to other peptidergic agents for long-term treatment.
- BPC 157 represents a promising therapeutic candidate for managing complex gastrointestinal conditions and promoting healing.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...